Clinical Trial Update: 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of triapine (3-AP) with high-dose cytarabine in adults with advanced hematologic malignancies has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Triapine (Triapine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 1 | Status: COMPLETED